{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fullerton&page=38&state=California",
    "query": {
      "state": "California",
      "city": "Fullerton",
      "page": 38
    },
    "page_size": 10
  },
  "pagination": {
    "page": 38,
    "page_size": 10,
    "total_count": 1113,
    "total_pages": 112,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fullerton&page=39&state=California&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fullerton&page=37&state=California&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-04T02:35:54.240Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02516423",
      "title": "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Solitary Osseous Plasmacytoma"
      ],
      "interventions": [
        {
          "name": "ixazomib",
          "type": "DRUG"
        },
        {
          "name": "lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "zoledronic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2016-11-29",
      "completion_date": "2025-09-30",
      "has_results": true,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-11-04T02:35:54.240Z",
      "location_count": 388,
      "location_summary": "Anchorage, Alaska • Burbank, California • Clovis, California + 267 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02516423"
    },
    {
      "nct_id": "NCT03665441",
      "title": "Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pancreatic Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "eryaspase",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine plus Abraxane",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan plus 5-FU plus leucovorin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ERYtech Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 512,
      "start_date": "2018-09-15",
      "completion_date": "2022-01-18",
      "has_results": true,
      "last_update_posted_date": "2022-10-18",
      "last_synced_at": "2026-11-04T02:35:54.240Z",
      "location_count": 14,
      "location_summary": "Scottsdale, Arizona • Fullerton, California • Sacramento, California + 11 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03665441"
    },
    {
      "nct_id": "NCT02445391",
      "title": "Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Estrogen Receptor Negative",
        "HER2/Neu Negative",
        "Invasive Breast Carcinoma",
        "Progesterone Receptor Negative",
        "Stage II Breast Cancer",
        "Stage IIA Breast Cancer",
        "Stage IIB Breast Cancer",
        "Stage III Breast Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 415,
      "start_date": "2015-10-20",
      "completion_date": "2031-03-29",
      "has_results": true,
      "last_update_posted_date": "2026-11-02",
      "last_synced_at": "2026-11-04T02:35:54.240Z",
      "location_count": 1023,
      "location_summary": "Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 634 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02445391"
    },
    {
      "nct_id": "NCT05787782",
      "title": "Validation of the Masimo INVSENSOR00063 in Febrile and Afebrile Subejcts",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Fever"
      ],
      "interventions": [
        {
          "name": "Masimo INVSENSOR00063",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Masimo Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Year and older"
      },
      "enrollment_count": 60,
      "start_date": "2023-02-23",
      "completion_date": "2023-03-02",
      "has_results": true,
      "last_update_posted_date": "2025-10-31",
      "last_synced_at": "2026-11-04T02:35:54.240Z",
      "location_count": 1,
      "location_summary": "Fullerton, California",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05787782"
    },
    {
      "nct_id": "NCT00806819",
      "title": "Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Nintedanib (BIBF1120)",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "B12",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone (or corticosteroid equivalent)",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "Folic Acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 718,
      "start_date": "2008-12",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2017-02-02",
      "last_synced_at": "2026-11-04T02:35:54.240Z",
      "location_count": 40,
      "location_summary": "Downy, California • Fountain Valley, California • Fullerton, California + 37 more",
      "locations": [
        {
          "city": "Downy",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Meriden",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00806819"
    },
    {
      "nct_id": "NCT02557100",
      "title": "Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Abatacept",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2015-11-19",
      "completion_date": "2019-03-28",
      "has_results": true,
      "last_update_posted_date": "2020-09-03",
      "last_synced_at": "2026-11-04T02:35:54.240Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02557100"
    },
    {
      "nct_id": "NCT06467357",
      "title": "Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Biliary Tract Cancer"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Rilvegostomig",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 620,
      "start_date": "2024-08-12",
      "completion_date": "2029-05-16",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-04T02:35:54.240Z",
      "location_count": 48,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Fullerton, California + 38 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06467357"
    },
    {
      "nct_id": "NCT05285553",
      "title": "MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Myopia"
      ],
      "interventions": [
        {
          "name": "MiSight 1 Day",
          "type": "DEVICE"
        },
        {
          "name": "Proclear 1 day",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "CooperVision, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "8 Years to 12 Years"
      },
      "enrollment_count": 900,
      "start_date": "2022-06-25",
      "completion_date": "2030-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-11-04T02:35:54.240Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Fullerton, California • La Mesa, California + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Ocoee",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05285553"
    },
    {
      "nct_id": "NCT04777331",
      "title": "A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinsons Disease"
      ],
      "interventions": [
        {
          "name": "Prasinezumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 586,
      "start_date": "2021-05-05",
      "completion_date": "2031-06-30",
      "has_results": true,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-11-04T02:35:54.240Z",
      "location_count": 31,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04777331"
    },
    {
      "nct_id": "NCT02245672",
      "title": "MGR001 / Advair Diskus Local Equivalence Study in Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)",
          "type": "DRUG"
        },
        {
          "name": "Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Pharma UK Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1128,
      "start_date": "2014-10",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2022-02-24",
      "last_synced_at": "2026-11-04T02:35:54.240Z",
      "location_count": 101,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 84 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Burbank",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02245672"
    }
  ]
}